Ligand for members of the frizzled family of seven transmembrane receptors . Can activate or inhibit canonical Wnt signaling, depending on receptor context . In the presence of FZD4, activates beta-catenin signaling. In the presence of ROR2, inhibits the canonical Wnt pathway by promoting beta-catenin degradation through a GSK3-independent pathway which involves down-regulation of beta-catenin-induced reporter gene expression . Suppression of the canonical pathway allows chondrogenesis to occur and inhibits tumor formation. Stimulates cell migration . Decreases proliferation, migration, invasiveness and clonogenicity of carcinoma cells and may act as a tumor suppressor. Mediates motility of melanoma cells (By similarity). Required during embryogenesis for extension of the primary anterior-posterior axis and for outgrowth of limbs and the genital tubercle . Inhibits type II collagen expression in chondrocytes (By similarity). .

Protein Wnt-5a Wnt5a Wnt-5a

Human;Rat;Mouse

WB IHC IF

Western blotting: 0.2-2μg/mL;1:250-2500 Immunohistochemistry: 5-20μg/mL;1:25-100 Immunocytochemistry: 5-20μg/mL;1:25-100 Optimal working dilutions must be determined by end user.

43kD

Wnt5a Wnt-5a

p22725

Polyclonal

Signal transduction;

Antigen-specific affinity chromatography followed by Protein A affinity chromatography

Liquid

500μg/mL

PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.

Store at +4℃ after thawing. For long-term storage, please store it at -20℃. Avoid repeated freeze / thaw cycles.